I, for one, would like to see some or all Cytodyn drug trials done under the auspices of the NIH. Pourhassen and others didn't want to do that for reasons that were never entirely clear. Outsiders are always in that situation so there may have been some good reasons there. I don't know.

But I do know that trial funding is a problem and approval by the FDA is a problem. NIH trials could solve those problems.

For major diseases, there are always NIH trials starting up. Cancer is a big priority with constant trials ongoing.

Another benefit would be less likelihood of any trial sabotage. Government institutions hate scandals more than private enterprises because it hurts legitimacy (or illusions of legitimacy) and funding of agencies in the future. There are more checks and balances there.

Given Cytodyn's situation, this looks like a good option to me.

Also, with government grants, the number of indications trialed for could be as many as Cytodyn wants.

Also, gov't trials are larger and probably more likely to be ended early if good efficacy is shown. We know by now how important trial quality is.